tradingkey.logo

Xenon Pharmaceuticals Inc <XENE.OQ> expected to post a loss of 91 cents a share - Earnings Preview

ReutersMay 9, 2025 9:32 PM
  • Xenon Pharmaceuticals Inc XENE.OQ XENE.O is expected to show a rise in quarterly revenue when it reports results on May 12 for the period ending March 31 2025

  • The Vancouver British Columbia-based company is expected to report revenue of $1.107 million, according to the mean estimate from 14 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Xenon Pharmaceuticals Inc is for a loss of 91 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had risen by about 0.3% in the last three months. ​

  • Wall Street's median 12-month price target for Xenon Pharmaceuticals Inc is $58.00​, above​ its last closing price of $35.54. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-0.85

-0.86

-0.84

Beat

2.4

Sep. 30 2024

-0.82

-0.82

-0.81

Beat

0.6

Jun. 30 2024

-0.69

-0.70

-0.75

Missed

-7.2​

Mar. 31 2024

-0.65

-0.66

-0.62

Beat

6.7

​​Dec. 31 2023

-0.73

-0.76

-0.64

Beat

15.7

Sep. 30 2023

-0.78

-0.77

-0.73

Beat

5.7​

Jun. 30 2023

-0.72

-0.70

-0.72

Missed

-3.3

Mar. 31 2023

-0.64

-0.62

-0.63

Missed

-1.4

This summary was machine generated May 9 at 21:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI